PLYMOUTH, Minn., Feb. 9, 2021 /PRNewswire/ InterShunt Technologies, Inc., an early-stage medical device company developing a novel catheter-based solution to reduce left atrial pressure in heart failure patients, announced
InterShunt Announces Equity Financing
Share this article
Share this article
ST. LOUIS, Jan. 11, 2021 /PRNewswire/ InterShunt Technologies, Inc., an early-stage medical device company developing a novel catheter-based solution to reduce left atrial pressure in heart failure patients, announced today the completion of an equity financing. Funding will be used to support the research and development of the Percutaneous Atrial Shunt Catheter System (PAS-C™ System). The round was led by Solas BioVentures with participation from Arsenal Capital Management and a select group of industry executives.
David Adair, MD, MBA, Managing Partner of Solas BioVentures stated, InterShunt s innovative and differentiated approach to create an interatrial shunt has the potential to provide significant clinical benefit in a space that has limited options. The ability to create a shunt without energy or hardware is attractive. Leaving nothing behind allows the body the best chance at superb out